United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $259.60, for a total value of $2,076,800.00. Following the sale, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $33,748. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
United Therapeutics Stock Up 0.6 %
Shares of United Therapeutics stock opened at $261.70 on Friday. The business's fifty day moving average price is $270.84 and its two-hundred day moving average price is $241.25. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The company has a market capitalization of $11.93 billion, a P/E ratio of 17.80, a PEG ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 1-year low of $158.38 and a 1-year high of $283.09.
Get
United Therapeutics alerts:
United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, beating the consensus estimate of $3.57 by $1.34. The firm had revenue of $516.00 million for the quarter, compared to the consensus estimate of $492.92 million. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. As a group, research analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current year.
Institutional Trading of United Therapeutics
Several hedge funds have recently added to or reduced their stakes in UTHR. Charter Oak Capital Management LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth $25,000. Cullen Frost Bankers Inc. bought a new stake in shares of United Therapeutics in the 2nd quarter worth $26,000. Guardian Wealth Advisors LLC bought a new stake in shares of United Therapeutics in the 3rd quarter worth $27,000. Ronald Blue Trust Inc. bought a new stake in shares of United Therapeutics in the 2nd quarter worth $28,000. Finally, Hallmark Capital Management Inc. bought a new stake in shares of United Therapeutics in the 2nd quarter worth $33,000. Institutional investors own 95.63% of the company's stock.
Analyst Ratings Changes
Several brokerages have recently commented on UTHR. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, November 3rd. Wedbush lifted their target price on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. HC Wainwright lifted their target price on United Therapeutics from $255.00 to $300.00 and gave the stock a "buy" rating in a research report on Thursday, November 3rd. Oppenheimer lifted their target price on United Therapeutics from $325.00 to $375.00 and gave the stock an "outperform" rating in a research report on Thursday, November 3rd. Finally, JPMorgan Chase & Co. lifted their target price on United Therapeutics from $240.00 to $265.00 and gave the stock an "overweight" rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $283.64.
About United Therapeutics
(Get Rating)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
